Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GSK-3 inhibitors: discoveries and developments.

M Alonso1, A Martinez

  • 1NeuroPharma, SA; Avda De la Industria 52, 28760 Tres Cantos, Madrid, Spain.

Current Medicinal Chemistry
|March 23, 2004
PubMed
Summary

Glycogen synthase kinase 3 (GSK-3) is a key therapeutic target for numerous diseases. Recent advancements in peptides and small molecules show promise for developing novel GSK-3 inhibitors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel entorhinal projection to the rat dentate gyrus: direct innervation of proximal dendrites and cell bodies of granule cells and GABAergic neurons.

The Journal of neuroscience : the official journal of the Society for Neuroscience·1996
Same author

Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses.

Gastroenterology·1996
Same author

Mutational analysis and secondary structure model of the RNP1-like sequence motif of transcription termination factor Rho.

Journal of molecular biology·1996
Same author

Residues in the RNP1-like sequence motif of Rho protein are involved in RNA-binding affinity and discrimination.

Journal of molecular biology·1996
Same author

Effects of continuous low-dose-rate brachytherapy on the rectum of the rat.

Radiation research·1996
Same author

Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice.

The American journal of tropical medicine and hygiene·1996

Area of Science:

  • Biochemistry
  • Pharmacology
  • Drug Discovery

Background:

  • Glycogen synthase kinase 3 (GSK-3) is a significant therapeutic target for various unmet medical needs.
  • GSK-3 inhibitors are being developed for conditions such as Alzheimer's disease, stroke, bipolar disorders, inflammation, cancer, and type II diabetes.

Purpose of the Study:

  • To review recent discoveries and developments in peptides and small molecules targeting GSK-3.
  • To highlight the growing interest and potential of GSK-3 as a therapeutic target.

Main Methods:

  • Literature review of recent scientific publications.
  • Analysis of academic and pharmaceutical research on GSK-3 inhibitors.

Main Results:

  • An exponential increase in GSK-3 inhibitor candidates in development over the past two years.
  • Identification of diverse peptide and small molecule approaches targeting GSK-3.

Conclusions:

  • GSK-3 inhibitors represent a promising area for drug development with significant clinical and economic potential.
  • Continued research into GSK-3 targeting agents is warranted for various pathologies.

Related Experiment Videos